October 2014

The Endothelin Pathway: A Protective or Detrimental Target of Bardoxolone Methyl on Cardiac Function in Patients with Advanced Chronic Kidney Disease?

Bardoxolone methyl has been reported to cause detrimental cardiovascular events in the terminated BEACON Phase III human clinical trial via modulation of the renal endothelin pathway. However, the…